Robert F. Kennedy Jr. Advocates for Stricter Drug Advertising Policies

Robert F. Kennedy Jr. has suggested that one significant approach for President Trump to enhance public health is by revisiting the advertising regulations surrounding consumer medications. Interestingly, he notes that the US and New Zealand are the only countries that permit pharmaceutical companies to market directly to consumers. This reliance on drug advertisements could potentially skew how health topics are covered in the media, creating some concern among viewers.

Currently, the Trump administration appears ready to address this concern, potentially making it harder and more expensive for pharmaceutical companies to reach patients directly.

Kennedy has pointed out that drug advertisements often emphasize certain benefits while glossing over possible risks. In alignment with this commitment to public health, there are discussions about introducing stricter oversight and ensuring consumers receive more transparent information about medications.

Reportedly, two main policies are under consideration. The first would mandate that drug manufacturers clearly disclose side effects associated with their products. This could extend the duration of TV commercials, thus inflating costs for drug companies. Additionally, an outright ban on direct consumer advertising could lead to legal challenges, presenting a practical hurdle for the administration.

Furthermore, some familiar with the proposals have mentioned that there may be a policy allowing pharmaceutical companies to write off their direct-to-consumer advertising as business expenses, which adds another layer to this complex discussion.

Recent analyses indicate that companies spent approximately $10.8 billion last year on consumer-targeted drug advertising. In just three months of 2025, spending by drugmakers reached around $729.4 million for the top ten brands. It’s clear that advertising plays a massive role in the pharmaceutical landscape.

Given public sentiment, many might be wary of misleading advertisements. A spokesperson for the National Broadcasting Agency has expressed concern that restricting these ads could impact revenue streams for various media outlets and raise First Amendment issues.

Interestingly, there’s some bipartisan momentum for this conversation. Independent Senators Bernie Sanders and Angus King have introduced legislation aimed at banning all direct-to-consumer advertising across multiple platforms. They believe that the American public is fed up with expensive and misleading drug commercials. A significant portion of the population—59%—supports the idea of banning pharmaceutical ads on television.

Despite the efforts from various stakeholders, it could be challenging to advance any legislation in this area, especially given the protections surrounding free speech. The American Medical Association has also shown support for curbing such advertisements, underscoring that the current approach may not necessarily result in healthier patients and could just drive up costs.